文献速递肝病

他汀类药物使用与原发性胆汁性胆管炎患者肝功能失代偿的关联:目标试验模拟研究

Association between statin use and hepatic decompensation in patients with primary biliary cholangitis: A target trial emulation study.
PubMed 文献 · Hepatology · 2026-02-02

本研究采用目标试验模拟设计,基于Mass General Brigham和Asan Medical Center两个电子健康记录数据库,纳入2001至2024年诊断为原发性胆汁性胆管炎的成人患者2889例,匹配443例他汀使用者与886例非使用者。中位随访3.8年,他汀使用与肝功能失代偿风险降低相关(HR 0.61,95%CI 0.38-0.97),并与主要不良肝脏结局复合终点风险降低相关(HR 0.58,95%CI 0.38-0.89)。

要点

  • 他汀使用与PBC患者肝功能失代偿风险降低相关(HR 0.61,95%CI 0.38-0.97)。
  • 他汀使用与主要不良肝脏结局复合终点风险降低相关(HR 0.58,95%CI 0.38-0.89)。
  • 分层分析显示不同数据来源和肝硬化状态亚组趋势一致。

核心结论

  • 他汀使用与PBC患者肝功能失代偿及主要肝脏事件风险降低持续相关,支持潜在保护效应。

研究设计与样本

  • 采用序贯目标试验模拟设计,基于Mass General Brigham和Asan Medical Center两个电子健康记录数据库,纳入2001至2024年诊断为PBC的成人患者2889例。
  • 他汀使用定义为累计持续时间≥90天,每月试验中他汀起始者按1:2倾向性评分匹配非使用者,最终443例他汀使用者匹配886例非使用者。

主要发现

  • 中位随访3.8年,他汀使用者中24例(5.4%)发生肝功能失代偿,非使用者中67例(7.6%)发生,HR 0.61(95%CI 0.38-0.97)。
  • 他汀使用与主要不良肝脏结局复合终点风险降低相关(HR 0.58,95%CI 0.38-0.89)。
  • 按数据来源分层敏感性分析:MGB HR 0.65,AMC HR 0.60;按肝硬化状态分层:肝硬化HR 0.70,无肝硬化HR 0.57,趋势一致。

临床怎么用

  • 在PBC患者中,他汀使用可能与降低肝功能失代偿和主要肝脏事件风险相关,临床决策时可综合考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Statins have been investigated for their potential to reduce liver-related complications in chronic liver diseases, but evidence in primary biliary cholangitis (PBC) remains limited. This study aimed to assess the association between statin use and the risk of hepatic decompensation using a target trial emulation (TTE) design. APPROACH AND RESULTS: We performed a sequential TTE using 2 electronic health record databases: Mass General Brigham (MGB, Boston, USA) and Asan Medical Center (AMC, Seoul, Korea). Adults diagnosed with PBC between 2001 and 2024 were eligible. Statin use was defined as a cumulative duration of ≥90 days. In each monthly trial, statin initiators were matched 1:2 to non-users using propensity score matching. The primary outcome was hepatic decompensation; the secondary outcome was a composite major adverse liver outcome (MALO), including decompensation, hepatocellular carcinoma, and liver transplantation. Among 2889 eligible patients, 443 statin users were matched to 886 non-users. Over a median follow-up of 3.8 years, hepatic decompensation occurred in 24 statin users (5.4%) and in 67 non-users (7.6%) [hazard ratio (HR), 0.61; 95% confidence interval (CI): 0.38-0.97]. Statin use was also associated with a reduced risk of MALO (HR, 0.58; 95% CI: 0.38-0.89). Sensitivity analyses stratified by data source (MGB, HR 0.65; AMC, HR 0.60) and cirrhosis status (HR 0.70 for cirrhosis; HR 0.57 for without) showed similar directional trends. CONCLUSIONS: Statin use was consistently associated with a lower risk of hepatic decompensation and major liver events in patients with PBC, supporting a potential protective effect.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Choi J, Xu J, Nguyen VH, et al. Association between statin use and hepatic decompensation in patients with primary biliary cholangitis: A target trial emulation study. Hepatology. 2026. PMID: 41627867. doi:10.1097/HEP.0000000000001701

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。